Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network

M. Rondy, J. Castilla, O. Launay, S. Costanzo, C. Ezpeleta, F. Galtier, K. de Gaetano Donati, Carmen Ezpeleta, A. Moren, Xabier Beristain, Judith Chamorro, Mercedes Gabari, Pilar Artajo, Francisco Lameiro, Laura Barrado, Maite Ortega, Montse Torres, José Javier García Irure, Fátima Irisarri, Manuel García CenozMarcela Guevara, Itziar Casado, Jorge Díaz, Iván Martínez-Baz, Jesús Castilla, Nezha Lenzi, Zineb Lesieur, Isabelle Bonmarin, Corinne Merle, Vincent Foulongne, Flavie Letois, Valérie Driss, Philippe Géraud, Arnaud Bourdin, Liliane Landreau, Amadou Konaté, Philippe Corne, Mustapha Sebbane, Kada Klouche, Marie Suzanne Léglise, Pierre Loulergue, Reem Kanaan, Florence Dumas, Anne Krivine, Sonia Moncilovic, Nadine Ali, Xavier Duval, Yolande Costa, Rachid Aït Naman, Yazdan Yazdapanah, Marion Caseris, Nathalie Dournon, Thomas Papo, Antoine Dossier, Hakim Bécheur, Anne Laure Pelletier, Hervé Mal, Armelle Marceau, Michel Aubier, Raphaêl Bories, Enrique Casalino, Christophe Choquet, Nadhira Houhou, Philippe Vanhems, Corinne Régis, Stéphane Jouneau, Fabrice Lainé, Pierre Tattevin, Luc Beuzit, Elise Thébault, Sophie Fey, Gisele Lagathu et Sophie Cha, Déborah Postil, Sébastien Alcoléa, Sylvie Rogez, Martine Valette, Bruno Lina, Katleen de Gaetano Donati, Roberto Cauda, Francesco Taccari, Rosaria Santangelo, Francesco Perlasca, Giovanni Fichera, Marianna Dara, Simona Costanzo, Licia Iacoviello, Marco Olivieri

Research output: Contribution to journalArticlepeer-review

Abstract

We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.

Original languageEnglish
Pages (from-to)1217-1224
Number of pages8
JournalHuman Vaccines and Immunotherapeutics
Volume12
Issue number5
DOIs
Publication statusPublished - May 3 2016

Keywords

  • case control studies
  • hospital
  • Influenza
  • Influenza vaccine
  • multicentre studies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network'. Together they form a unique fingerprint.

Cite this